Bessemer Group Inc. Has $56.62 Million Stake in Kenvue Inc. (NYSE:KVUE)

Bessemer Group Inc. reduced its stake in Kenvue Inc. (NYSE:KVUE) by 3.3% during the first quarter, HoldingsChannel reports. The firm owned 2,361,176 shares of the company’s stock after selling 79,922 shares during the quarter. Bessemer Group Inc.’s holdings in Kenvue were worth $56,620,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in KVUE. SRS Capital Advisors Inc. increased its holdings in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares in the last quarter. Continuum Advisory LLC grew its holdings in shares of Kenvue by 2,071.1% during the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company’s stock worth $47,000 after purchasing an additional 1,864 shares during the last quarter. Clarity Asset Management Inc. bought a new stake in shares of Kenvue during the fourth quarter worth about $45,000. SBI Securities Co. Ltd. acquired a new position in shares of Kenvue in the fourth quarter valued at approximately $46,000. Finally, Versant Capital Management Inc raised its holdings in Kenvue by 77.9% in the 1st quarter. Versant Capital Management Inc now owns 3,415 shares of the company’s stock valued at $82,000 after buying an additional 1,495 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on KVUE shares. Citigroup reiterated a “neutral” rating on shares of Kenvue in a research report on Friday, June 13th. Barclays lifted their price target on shares of Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a report on Monday, May 12th. Evercore ISI initiated coverage on Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price objective for the company. Canaccord Genuity Group lifted their target price on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, UBS Group upped their price target on Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Friday, May 9th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.33.

Kenvue Stock Performance

Shares of KVUE opened at $21.17 on Thursday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The firm’s fifty day simple moving average is $22.93 and its two-hundred day simple moving average is $22.39. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17. The stock has a market capitalization of $40.62 billion, a P/E ratio of 38.49, a price-to-earnings-growth ratio of 3.29 and a beta of 0.98.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The company had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. During the same period in the previous year, the business earned $0.28 EPS. The firm’s revenue was down 3.9% compared to the same quarter last year. As a group, analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.87%. The ex-dividend date was Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.